Virginia Tech® home

Virtual Seminar: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial

Insert your title here

Your Text Here
Shahid Nimjee, M.D., Ph.D.

Shahid Nimjee, M.D., Ph.D.

Associate Professor of Neurological Surgery
Co-Director, Stroke Center
Wexner Medical Center
The Ohio State University

Virtual Timothy A. Johnson Medical Scholar Lecture: Von Willebrand Factor Inhibition in Acute Ischemic Stroke: From Target to Trial

Sept. 23, 2022

1 to 2 p.m.

View Speaker Profile
Download Flyer

About this Seminar

Acute ischemic stroke (AIS) is the leading cause of combined morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only approved pharmacological treatment for AIS but is limited to treating patients within 4.5 hours of stroke onset because of the risk of intracranial hemorrhage. Moreover, it is ineffective in treating large vessel occlusion (LVO) stroke. Endovascular mechanical thrombectomy (MT) effectively recanalizes LVO stroke but it is  limited to highly-specialized hospitals, leaving the vast majority without timely acute treatment. Dr. Nimjee hypothesizes that targeted von Willebrand Factor (VWF) inhibition by BB-031 will recanalize arterial thrombosis in a canine model of LVO stroke. Utilizing a canine embolic middle cerebral artery occlusion (eMCAO) model of LVO stroke, his lab assessed BB-031 administration at 0.5mg/kg 6 hours after stroke induction on platelet activity by PFA-100, vessel recanalization by digital subtraction angiography, infarct volume and intracranial hemorrhage by MRI. BB-031 administration after 6 hours of LVO stroke resulted complete inhibition of platelet activity. Moreover, it recanalized MCAO to >TICI 2A in 62.5% and >TICI 2B in 50% of canines (n=8). Negative control group demonstrated no revascularization (n=7). Recanalization resulted in reduced infarct volume compared to negative control (p<0.05). BB-031 administration induced no intracranial hemorrhage. VWF inhibition by BB-031 completely inhibited platelet activity, and effectively recanalizes LVO when administered 6 hours after stroke onset. Recanalization resulted in reduced infarct volume, without any incidence of intracranial hemorrhage. Targeted therapy against VWF represents a robust yet safe approach to treat AIS.

Additional Details

This is a free event hosted by the Fralin Biomedical Research Institute and the Virginia Tech Carilion School of Medicine. The Timothy A. Johnson Medical Scholar Lecture Series hosts clinician scientists who are exploring frontiers of medicine. These lectures are principally intended for Virginia Tech Carilion School of Medicine students and Virginia Tech students in the Translational Biology, Medicine, and Health graduate program. Virginia Tech and Carilion Clinic faculty, staff, and students may also attend.

fbri logo

You May Also Be Interested In...

  • Home Item
    Social Learning in Borderline Personality Disorder
    Social Learning in Borderline Personality Disorder , home

    April 4, 2025, 11:00 a.m. | Sarah Fineberg, M.D., Ph.D., Assistant Professor, Department of Psychiatry, Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research

  • Home Item
    Bringing Precision Medicine to Psychiatry
    Bringing Precision Medicine to Psychiatry , home

    April 10, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jordan Smoller, M.D., Sc.D., MGH Trustees Endowed Chair in Psychiatric Neuroscience; Professor of Psychiatry, Harvard Medical School; Professor of Epidemiology, T.H. Chan Harvard School of Public Health; Director, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital | Maury Strauss Distinguished Public Lecture

  • Home Item
    Extracellular Vesicles in the Pathogenesis, Diagnosis and Treatment of the Heart
    Extracellular Vesicles in the Pathogenesis, Diagnosis and Treatment of the Heart , home

    April 11, 2025, 11:00 a.m. | Susmita Sahoo, Ph.D., Associate Professor, Department of Medicine and Cardiology, Icahn School of Medicine at Mount Sinai | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research

  • Home Item
    A Human-Centric View of Cerebellar Development
    A Human-Centric View of Cerebellar Development , home

    April 18, 2025, 11:00 a.m. | Kathleen Millen, Ph.D., Professor, Department of Pediatrics/Genetics, Associate Director and Principal Investigator, Seattle Children's Hospital Research Institute, The University of Washington School of Medicine | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute

  • Home Item
    Molecular and Neurobiological Studies in Rett Syndrome and Other MECP2 Disorders
    Molecular and Neurobiological Studies in Rett Syndrome and Other MECP2 Disorders , home

    May 1, 2025, 5:30 p.m. (Reception at 5 p.m.) | Huda Zoghbi, M.D., Professor, Pediatrics, Molecular and Human Genetics, Neuroscience, and Neurology; Director, Jan and Dan Duncan Neurological Research Institute, Baylor College of Medicine; Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture

  • Home Item
    A Novel Bispecific Antibody to Target the Brain Tumor Microenvironment
    A Novel Bispecific Antibody to Target the Brain Tumor Microenvironment , home

    May 2, 2025, 11:00 a.m. | Khuson Yun, Ph.D., Associate Professor, Department of Neurology, Houston Methodist Chair, Neurodegenerative Disease Research, Houston Methodist Research Institute, Weill Cornell Medical College | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke